marstacimab   Click here for help

GtoPdb Ligand ID: 13403

Synonyms: Hympavzi® | marstacimab-hncq
Approved drug
marstacimab is an approved drug (EMA & FDA (2024))
Compound class: Antibody
Comment: Marstacimab (PF-06741086) is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI) [4]. The antibody blocks the inhibitory effect of TFPI on the FVIIa-TF complex interaction with coagulation factor Xa. This mechanism is proposed to increase coagulation activity of both the intrinsic and extrinsic coagulation pathways, for example in patients with severe haemophilia A or B.
No information available.
Summary of Clinical Use Click here for help
Marstacimab (PF-06741086) was progressed as a therapeutic candidate for the treatment of hemophilia A or B. It was granted FDA orphan designation in May 2016 as a prophylactic therapy for hemophilia A and hemophilia B patients. Full FDA approval was granted in October 2024, for the prevention/reduction of bleeding episodes related to hemophilia A or B [2]. EMA approval followed in November 2024.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03938792 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Phase 3 Interventional Pfizer
NCT02974855 PF-06741086 Multiple Dose Study in Severe Hemophilia Phase 2 Interventional Pfizer
NCT02531815 Dose Escalation Study of PF-06741086 In Healthy Subjects Phase 1 Interventional Pfizer 1
NCT03363321 PF-06741086 Long-term Treatment in Severe Hemophilia Phase 2 Interventional Pfizer 3